{"nctId":"NCT01561898","briefTitle":"A Long-Term Study of JNS007ER in Patients With Schizophrenia","startDateStruct":{"date":"2006-06"},"conditions":["Schizophrenia"],"count":228,"armGroups":[{"label":"Paliperidone extended-release (JNS007ER)","type":"EXPERIMENTAL","interventionNames":["Drug: Paliperidone extended-release (JNS007ER)"]}],"interventions":[{"name":"Paliperidone extended-release (JNS007ER)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients diagnosed with schizophrenia\n* Patients who have given their own consent in writing to participate in the study\n* Patients untreated with antipsychotics within 28 days before the screening test\n* Patients who have completed Study JNS007ER-JPN-S31, or those who continued the study at least up to the evaluation at 2 weeks and subsequently discontinued the study due to insufficient efficacy\n* Patients participating in Study JNS007ER-JPN-S31 and whose ratio of treatment to the evaluation at 2 weeks is â‰¥75%\n\nExclusion Criteria:\n\n* Patients diagnosed with a mental disease other than schizophrenia\n* A total PANSS score \\> 120 at baseline\n* Substance-related disorders\n* Parkinson's disease complications\n* Current or a past history of convulsive disease such as epilepsy\n* Current or a past history of cerebrovascular accident\n* Diabetes mellitus\n* Significant hepatic or renal impairment\n* Significant cardiovascular disorders\n* Abnormal results of hematological examination, blood chemistry test and urinalysis at screening\n* Pregnant women, breast-feeding mothers, and patients who wish pregnancy during the study period or those whose pregnancy test at screening was positive\n* Contraindications to risperidone products\n* Patients who discontinued Study JNS007ER-JPN-S31 due to an adverse event not related to the underlying disease\n* Patients judged inadequate by the investigator to participate in the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Change From Baseline in Positive and Negative Syndrome Scale (PANSS)","description":"PANSS is a medical scale that assesses various symptoms of schizophrenia. The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). The total score is the sum of all 30 PANSS items, with a range of 30 (absent) to 210 (extreme ill).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.4","spread":"31.93"},{"groupId":"OG001","value":"-11.1","spread":"20.84"},{"groupId":"OG002","value":"-17.2","spread":"22.15"},{"groupId":"OG003","value":"2.8","spread":"20.67"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Clinical Global Impression - Severity (CGI-S)","description":"The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a patient. A rating of 1 is equivalent to \"Normal, not at all ill\" and a rating of 7 is equivalent to \"Among the most extremely ill patients\".","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"1.27"},{"groupId":"OG001","value":"-0.6","spread":"1.20"},{"groupId":"OG002","value":"-0.7","spread":"1.24"},{"groupId":"OG003","value":"0.1","spread":"1.01"}]}]}]},{"type":"PRIMARY","title":"Incidence of Adverse Events","description":"The incidence of adverse events was measured by the percentage of patients who presented one or more adverse events.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":228},"commonTop":["Blood prolactin increased","Nasopharyngitis","Schizophrenia","Weight increased","Extrapyramidal disorder"]}}}